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1Chapter
Prevalence and Treatment of 
Constipation in Patients with 
Alpha-Synuclein Pathology
Charles M. Lepkowsky
Abstract
α-Synuclein “Lewy body” pathology is the basis of Parkinson’s disease (PD) and 
neurocognitive disorder with Lewy bodies (NCDLB), sometimes called Lewy body 
dementia. In patients with α-synuclein pathology, constipation, obstipation and 
impaction are almost universal symptoms, whose treatment represents a significant 
burden on health care economies. Description is given of the specific mechanisms 
through which α-synuclein pathology induces these symptoms, and through which 
the use of acetylcholinesterase inhibitors (AChEIs) might significantly reduce them. 
Four case studies are presented testing the hypothesis that the use of the cholinergic 
agonist donepezil might reduce the symptom of constipation in four patients with 
NCDLB or PD at different stages of disease progression. Outcomes are presented, 
as well as follow-up data at 6-, 12-, and 18-month intervals. The potential use of 
donepezil to reduce the symptoms of constipation in patients with α-synuclein 
pathology is discussed.
Keywords: constipation, α-Synuclein pathology, Parkinson’s disease, neurocognitive 
disorder with Lewy bodies, Lewy body dementia, acetylcholinesterase inhibitors 
(AChEIs)
1. Introduction
Longevity has increased significantly over the past four decades [1], bringing 
with it a significant increase in the number of older adults affected by neurocogni-
tive diseases (formerly called dementias) [2]. Worldwide, the number of people 
diagnosed with neurocognitive disease was 46.8 million in 2015, and 50 million 
in 2017. This figure is expected to exceed 75 million by 2030, and 131.5 million by 
2050 [3–5]. Approximately 67% of dementia diagnoses are assigned to Alzheimer’s 
disease (AD), 22% to neurocognitive disorder with Lewy bodies (NCDLB) (previ-
ously called Lewy body dementia), and the remaining 9% to Parkinson’s disease 
(PD) [2].
According to the US Census Bureau, the Center for Medicare and Medicaid 
Services (CMS) and the U.S. Burden of Disease Collaborators, the largest increases 
in annual payments for treatment and long-term care for older adults were for 
those diagnosed with neurocognitive disease. Per capita, PD and NCDLB repre-
sent more than their numeric percentage of this expense, which grew 113 percent 
between 1990 and 2010. Worldwide in 2015, the estimated economic burden of 
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neurocognitive disease was $818 billion, representing 1.09% of global gross domes-
tic product. Currently, the global cost of neurocognitive disease is estimated above 
$1 trillion, and is expected to increase fourfold to more than $4 trillion by 2050 
[2, 6, 7]. As the occurrence of neurocognitive disease increases, early and accurate 
diagnosis becomes increasingly important for appropriate treatment, as well as 
containment of the cost associated with care delivery.
So what are PD and NCDLB, and why do they cost so much to treat?
PD and NCDLB are α-synuclein “Lewy body “pathologies characterized by 
a wide range of cognitive, motor, and autonomic symptoms, including consti-
pation, obstipation, and impaction [8]. The disproportionate cost of care for 
α-synucleopathologies is due to their widely varied symptom presentation, com-
bined with significant, progressive debilitation within systems affected by Lewy 
bodies. Lewy bodies are abnormal intracellular aggregations of α-synuclein protein 
[9]. α-synuclein pathology, α-synucleopathology, and α-synucleinopathy are all 
terms used to describe impairment of neural functioning due to the presence of 
Lewy Bodies (aggregates of α-synuclein protein) [10].
AD Alzheimer’s Disease
PD Parkinson’s Disease
NCDLB Neurocognitive disorder with Lewy Bodies
CNS Central nervous system
ANS Autonomic nervous system
PNS Peripheral nervous system
ENS Enteric nervous system
MCI Mild cognitive impairment
ACh Acetlycholine
AChE Acetylcholinesterase
AChEI Acetylcholinesterase inhibitor
REM Rapid eye movement
RBD REM behavior disorder
RSWA REM sleep without dystonia
MP Myenteric plexus
SMCP Submucosal colonic plexus
ER Endoplasmic reticulum
MMSE Mini mental status exam
QDRS Quick dementia rating system
LBCRS Lewy body composite risk score
OTC Over the counter
HS Taken daily
PRN As needed
MRI Magnetic resonance imaging
CMS Center for medicare and medicaid services
APA American Psychological Association
Table 1. 
Abbreviations.
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Pertinent to the topic of constipation, escalating gastric immotility in PD and 
NCDLB compromises mobility, sleep, cognition, and mood, increasing the cost of 
care, and potentially debilitating and/or dramatically reducing the quality of life for 
patients [11–17]. Although gastric immotility is a prevalent symptom characteristic of 
α-synuclein disorders, constipation, obstipation, and impaction are rarely a focus of 
treatment for patients with PD and NCDLB [18]. When PD and NCDLB constipation, 
obstipation, and impaction are addressed, primary care physicians typically recom-
mend conventional (often over-the-counter) treatments, despite data demonstrat-
ing that such treatments are ineffective with this population [12]. In order to make 
accurate diagnosis and assign appropriate and effective treatment, it is necessary to 
understand constipation, obstipation, and impaction as symptomatic manifesta-
tions of Lewy (α-synuclein) pathology in the enteric nervous system (ENS), and 
the specific mechanisms through which synuclein pathology impairs bowel motility. 
Medical intervention can then be selected based on the use of medications known to 
counteract those mechanisms. The effectiveness of evidence-based medical interven-
tion can be evaluated through large data set studies, and/or longitudinal case studies.
In this chapter, Lewy pathology in PD and NCDLB and its symptomatic mani-
festations in the ENS will be described. The specific mechanisms through which 
α-synucleopathology causes those symptoms will be explained, followed by a 
description of the mechanisms though which specific medications counter those of 
α-synuclein proteins. A series of case studies will be described, in which four patients 
at different stages of disease progression with NCDLB or PD were each treated using 
medication with demonstrated effectiveness for countering the mechanisms underly-
ing α-synucleinopathy in the ENS. Outcomes will be reviewed at 6, 12, and 18 month 
follow-up intervals, followed by a discussion of implications for future research and 
practice. Abbreviations used in this chapter are summarized in Table 1.
2. α-Synuclein pathology: Lewy bodies in PD and NCDLB
Unlike Alzheimer’s disease (AD), which is associated with presence of two pro-
teins in the central nervous system (CNS), amyloid-β (Aβ) and tau, PD and NCDLB 
are diseases characterized by the presence of Lewy bodies, pathologic aggregates 
of the synaptic protein α-synuclein. In PD and NCDLB, Lewy bodies appear not 
only in the CNS, but also in the autonomic nervous system (ANS), the peripheral 
nervous system (PNS) and the enteric nervous system (ENS), spreading from one 
nervous system area to the next over time [19, 20]. In PD and NCDLB patients, 
there is evidence that Lewy bodies travel from the gut to the brain, or vice-versa [21, 
22]. Lewy bodies aggregate not only near the nucleus of the neuron, but even more 
abundantly in neurites (axons and dendrites) [23].
2.1 Symptomatic manifestations of α-synuclein pathology
While amyloid-β (Aβ) and tau pathology in AD are associated almost exclu-
sively with cognitive impairment in the CNS, Lewy pathology in PD and NCDLB is 
heterogeneous in its presentation. Not every PD or NCDLB patient has the same, or 
all, α-synuclein pathology symptoms.
Most Lewy body patients present with disordered sleep: REM Sleep Behavior 
Disorder (RBD), and especially REM sleep without atonia (RSWA). They act out 
their dreams, sometimes injuring their bed partner, or remaining sleepless at night 
and drowsy all day [24]. Many Lewy body patients present with ANS dysfunc-
tion, including urinary incontinence, constipation, erectile dysfunction, coronary 
dysfunction, or orthostatic hypotension, which increases the likelihood of injury 
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due to falling [25, 26]. Lewy body patients sometimes present with sensory dysfunc-
tion, losing their sense of smell (anosmia) [27], and/or seeing colors differently 
[28]. Some Lewy body patients initially present with late life onset depression, with 
or without visual or auditory hallucinations, delusions, and anxiety [29]. Lewy 
body patients sometimes initially present with cognitive impairment, including 
attentional deficits, short-term memory loss, and/or difficulty with concentration 
or word-finding. Most often these symptoms are functionally diagnosed as Mild 
Cognitive Impairment (MCI), and frequently, later in symptom progression as AD, 
which is a common misdiagnosis [30]. Lewy body patients presenting with evolv-
ing Parkinsonian features (including shuffling gait, weakness, pain in muscles and 
joints, and/or tremor) are most often diagnosed with PD, which might be correct, or 
might be a misdiagnosis overlooking or minimizing the relevance of other symptoms 
listed above [31]. In some Lewy body patients, Parkinsonian features might not 
appear at all, or until long after other symptoms have become more prevalent [32].
Constellations of three or more of these symptom presentations are consid-
ered reliable prodromal indicators of α-synucleopathology, as well as differential 
diagnostic indicators distinguishing NCDLB from AD [8]. Proper identifica-
tion of prodromal Lewy body symptoms for early and accurate diagnosis of 
α-synucleopathology reduces the likelihood of misdiagnosis, and facilitates early 
treatment intervention to minimize or delay the emergence of multi-nervous 
system symptoms that impair functioning and reduce quality of life, with the 
consequent benefit of containing the cost of care delivery. Early diagnosis has been 
hindered more by general unawareness of prodromal symptom constellations with 
demonstrated predictive accuracy for α-synucleopathology [8] than by an actual 
lack of reliable biomarkers for α-synucleopathology [33].
Although Lewy body patients demonstrate wide variation in symptom presenta-
tion, the symptom almost universal to patients diagnosed with PD and NCDLB is 
constipation, which can lead to obstipation and/or impaction [14, 26, 34–44]. The 
uniformity of gastric immotility in patients with PD and NCDLB suggests that 
α-synuclein pathology directly affects the enteric nervous system (ENS).
2.2 Symptomatic manifestations of α-synuclein pathology in the ENS
Because gastric immotility is such a consistent symptom feature of PD and 
NCDLB, much research has focused on whether or to what extent Lewy pathol-
ogy occurs in the ENS of PD & NCDLB patients. Research data consistently 
demonstrate that abnormal α-synuclein proteins aggregate in the ENS of patients 
diagnosed with PD and NCDLB, with symptomatic manifestation as gastric immo-
tility [14, 26, 34–44]. In patients diagnosed with PD, symptoms frequently include 
increased colonic transit time [45] and impaired gastric emptying [46]. In PD 
patients, constipation is at least three times as prevalent as it is among the general 
population [47], and several researchers believe that constipation is a universal 
feature of PD [48]. In both PD and NCDLB, the symptom of bowel immotility often 
presents years before other diagnostic features [47, 49–53] sometimes as much as 
20 years before the emergence of others symptoms leading to the diagnosis of PD 
or NCDLB [17]. This occurs so frequently that many experts suggest that bowel 
immotility is a prodromal symptom for both PD and NCDLB [17, 21, 25, 37, 54–57].
3. The mechanism of α-synuclein impairment of the ENS
In patients with PD and NCDLB, high concentrations Lewy bodies (α-synuclein 
protein aggregates) are found in the myenteric plexus (MP) [56, 58–63] and the 
5Prevalence and Treatment of Constipation in Patients with Alpha-Synuclein Pathology
DOI: http://dx.doi.org/10.5772/intechopen.81010
colonic submucosal plexus (CSMP) [40]. 95% of innervation in the MP and the 
CSMP is cholinergic, and the CSMP is innervated by the MP [64]. As in other 
neurotransmitter pathways, Lewy bodies in the MP and CSMP do not appear 
exclusively in the form of large aggregations of α-synuclein protein near the 
nucleus. Small aggregations of α-synuclein and other proteins aggregate even more 
abundantly in neurites (axons and dendrites) [65]. The abundance of Lewy bodies 
in the predominantly cholinergic neurotransmitter pathways innervating the MP 
and CSMP interferes with cholinergic neurotransmission.
The specific biochemical mechanisms posited for α-synuclein pathology-based 
reduction of cholinergic functioning include endoplasmic reticulum (ER) stress, 
blockage in endoplasmic reticulum (ER)-to-Golgi vesicular trafficking, and mito-
chondrial dysfunction, all of which contribute to α-synuclein-induced cell death 
[66–68]. The degeneration of cholinergic neurons leads to a decline in levels of 
acetylcholine (ACh) [69]. The loss of cholinergic function in the MP and the CSMP 
reduces or eliminates signals that induce and maintain peristalsis, symptomatically 
manifesting as constipation, obstipation, and/or impaction [8, 13, 17, 23, 44, 46, 52, 
70–73]. The presence of Lew bodies in the MP and CSMP predates cognitive and 
motor functional manifestations of α-synuclein diseases [42, 61] so consistently 
that it has been nominated as a potential biomarker for α-synuclein pathology [74].
3.1 Potential exacerbation of ENS symptoms by anti-Parkinson medication
In both PD and NCDLB, α-synuclein patients with Parkinsonian features are 
often prescribed L-dopa agents such as carbidopa-levodopa (known also by the 
brand names Sinemet and Stalevo) in order to preserve gait, balance, and other 
basic motor functions [18, 75, 76]. Complicating or exacerbating gastric immotil-
ity due to α-synuclein ENS pathology, carbidopa-levodopa’s potential side effects 
include constipation [77]. Other medications frequently used to mitigate resting 
tremor in PD and NCDLB include trihexyphenidyl (marketed as Artane or Trihex) 
and benztropine mesylate (marketed as Cogentin). Each has been identified as an 
anticholinergic medication, which accordingly can also exacerbate gastric immotil-
ity through suppression of the cholinergic neurotransmitter pathways innervating 
the ENS [76, 78–80].
4. The mechanism of symptom relief for cholinergic α-synuclein 
pathology: cholinergic agonist use in NCDLB and PD
The symptomatic features of PD and NCDLB have long been known to include 
cholinergic neural deficits and functional impairment [81–87]. Over time, it has 
become increasingly evident that α-synuclein pathology is the basis of cholin-
ergic impairments in PD and NCDLB [82, 87, 88].1 With the hope of mitigating 
α-synuclein cholinergic impairment [29, 65, 88, 91, 92], cholinergic agonists such as 
acetylcholinesterase inhibitors (AChEIs) are prescribed to NCDLB and PD patients. 
AChEIs include tacrine, galantamine, rivastigmine, and donepezil.
Low doses of tacrine have been associated with reductions of motor symptoms 
in PD patients [80] and galantamine [93]. Rivastigmine has been used to reduce 
neuropsychiatric symptoms and improve cognitive function as measured by the 
1 Cholinergic impairment does not appear to be a consistent finding in Alzheimer’s disease (AD) [86, 91]. 
Research consistently demonstrates that autonomic dysfunction is a feature of PD and NCDLB, but not 
AD [25, 39, 82, 89], and that alpha-synuclein expression is increased in NCDLB and PD, but not in AD [35, 
41, 90]. For this reason, AD is not included in this discussion.
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Mini-Mental State Exam (MMSE) [94] in patients with NCDLB [95–98]. In PD 
patients, however, the use of Rivastigmine to improve cognition has also been 
associated with higher rates of nausea, vomiting, and tremor [99].2
Donepezil has been used to improve cognition and reduce hallucinations and 
delusions in PD patients with cognitive impairment (suggesting that they are in fact 
NCDLB patients) [107]. 5–10 mg daily dosages of donepezil used in conjunction 
with antiparkinsonian therapy produced significant reduction in psychotic symp-
toms in PD patients (again, likely misdiagnosed NCDLB patients), without appar-
ent side effects or exacerbation of Parkinsonian symptoms [108]. An early study 
suggested that treatment of NCDLB with donepezil was sometimes associated with 
an increase in Parkinsonian features [109]. However, a large body of subsequent 
research indicates that donepezil reduces neurocognitive symptoms in patients with 
NCDLB without worsening Parkinsonian features [110–120], and a Cochrane data-
base systematic review of previous research using cholinergic agonists to treat PD 
& NCDLB found that donepezil produced consistent reduction in neurocognitive 
symptoms without exacerbation of Parkinsonian features or other side effects [121].
When compared to other acetylcholinesterase inhibitors including Galantamine 
and Rivastigmine for use with patients diagnosed with PD and NCDLB, donepezil 
has performed well, improving cognition [122], but with fewer side effects [123]. 
PD and NCDLB patients treated with donepezil demonstrated significant improve-
ments in cognition and behavior which disappeared when donepezil was with-
drawn, and later showed restoration of treatment gains upon recommencement of 
donepezil [124]. In patients with NCDLB, long-term administration of donepezil at 
10 mg/day has been shown to improve cognitive function for up to 52 weeks without 
increasing the risk of Parkinsonian features or other clinically significant safety 
events [125, 126].
4.1 Donepezil for symptom relief of constipation
Conventional treatments for constipation have proven ineffective in older 
patients in residential settings, especially for patients with neurocognitive disorders 
[12]. Recalling that 95% of the innervation of the MP and CSMP in the ENS is 
cholinergic [64], it is interesting to note that donepezil has been shown to reduce 
ANS symptoms including constipation in nongeriatric affective patients [127]. 
Donepezil increases cholinergically mediated bowel contractions as much as 477% 
in patients suffering from severe intestinal dysmotility [128]. The mechanisms 
through which donepezil mitigates these symptoms is twofold. AChEIs like donepe-
zil inhibit the action of the ACh-hydrolyzing enzyme acetylcholinesterase (AChE), 
increasing ACh levels, with consequent reduction in symptoms associated with 
progressive cholinergic dysfunction [69]. Donepezil is a specific, reversible AChE 
inhibitor [129, 130]. Donepezil also interacts independently with neuronal nicotinic 
ACh receptors [131]. Donepezil’s dual action has made it a long-standing choice for 
countering cholinergic impairment [69, 124, 131].
4.2 A hypothetical model for symptom relief of cholinergic α-synuclein 
pathology in the ENS
On the basis of substantial research a) linking constipation in patients with 
NCDLB and PD to α-synucleopathology-based impairment of cholinergic function 
in the MP and CSMP in the ENS, b) demonstrating that the use of the donepezil as 
2 Rare, potentially dangerous side effects of cholinergic agonists include rhabdomyolysis and neuroleptic 
malignant syndrome (NMS) [100–106].
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a cholinergic agonist mitigates cholinergic impairment in α-synuclein pathology 
patients, and c) showing that the use of the donepezil increases bowel motility 
in non-geriatric patients with gastric immotility, it was postulated that the use of 
donepezil might counter α-synuclein pathological impairment of the MP and CSMP 
in patients with NCDLB and PD, leading to increased bowel motility and a conse-
quent reduction in the symptom of constipation.
PD patients and NCDLB patients with significant Parkinsonian features are 
frequently prescribed L-dopa agents like carbidopa-levodopa (known also by the 
brand name Sinemet) to preserve balance, gait, and other basic motor functions 
[31, 76]. Carbidopa-Levodopa’s potential side effects include constipation [77]. 
Accordingly, it was postulated that the use of donepezil might have specific benefit 
in reducing constipation in patients with PD and NCDLB receiving L-dopa agents 
like carbidopa-levodopa.
To test these hypotheses, in a series of case studies donepezil was prescribed 
to four PD and NCDLB patients at different stages of disease progression, each 
suffering from constipation, obstipation, and/or impaction. Discussion of other 
diagnoses, symptoms, or treatments is limited, in order to make the case studies 
as brief as possible, while maintaining focus on donepezil’s potential for reducing 
constipation, obstipation, and impaction.
5. Four case studies: methods
5.1 Case study #1
Mr. A. was a non-Hispanic white male 50–55 years of age. He had been diag-
nosed with PD. His presenting symptoms included depression, transient hand 
tremor, cognitive interference resulting in permanent disability work status, lower 
back pain, insomnia, and significant constipation, with frequency of bowel move-
ments about once a week. For treatment of his Parkinsonian symptoms, the patient 
had been treated for 2 years with carbidopa-levodopa (Sinemet) and pramipexole 
(Mirapex) (both dopamine agonists). He had also been prescribed acetaminophen/
oxycodone (Percoset) for back pain, and dronabinol (Marinol) for pain and insom-
nia. For constipation, he had been advised to use over the counter (OTC) products 
including stewed prunes, prune juice, psyllium (fiber), and Senokot laxative/stool 
softener. None of the OTC remedies had produced any reduction in the symptom of 
constipation.
Donepezil was prescribed at a starting dose of 5 mg per day. Within 2 weeks, 
the patient reported that his frequency of bowel movements had increased to every 
other day. After 4 weeks, the frequency of bowel movements had increased to once 
a day. There was no increase in Parkinsonian features or other clinically significant 
symptoms, nor was there emergence of new symptoms.
5.2 Case study #2
Ms. B. was a non-Hispanic white female 65–70 years of age. She had not yet 
received a neurocognitive or Parkinsonian diagnosis, but had been diagnosed with 
late-life onset of acute anxiety and depression without suicidal ideation, in addition 
to standing diagnoses of hypertension, hypothyroid, and possible sleep apnea. For 
several years she had received prescriptive Spironolactone 25 mg HS (as a diuretic), 
Levothyroxine 75 mcg HS (for hypothyroid), and most recently Lorazepam 1 mg 
PRN (for anxiety). Her presenting symptoms included cognitive interference 
(short-term memory loss and difficulty word-finding), agitation, panic attacks, 
Constipation
8
dysphoria, insomnia (onset, median, and terminal waking), restless sleep (which 
her spouse described as talking and flailing in her sleep), and constipation (of 
approximately 5 years). At intake, the patient reported that the frequency of bowel 
movements was approximately twice a week. She had tried a variety of OTC and 
dietary remedies, all of which had been ineffective. The patient was administered 
the MMSE [94], the Quick Dementia Rating Scale (QDRS) [132] and the Lewy 
Body Composite Risk Score (LBCRS) [133]. Her scores indicated mild cognitive 
impairment (MCI) and suggested neurocognitive impairment consistent with that 
found in patients with Lewy body disorders. In combination, the symptoms of 
MCI, late-life onset depression, and sleep disturbance (possible REM sleep behavior 
disorder or RSBD and/or REM sleep without atonia, or RSWA) [105] are considered 
prodromal for NCDLB. A neurological evaluation and a sleep study were ordered 
in order to gather confirmatory evidence. The neurological assessment confirmed 
MCI, and an MRI showed reduced cerebral (white matter) volume. RSBD/RSWA 
was confirmed by the sleep study.
Donepezil was prescribed at a starting dose of 5 mg per day. Within 3 weeks the 
patient reported that her frequency of bowel movements had increased to about 
every other day. After 5 weeks, she reported daily bowel movements. There was no 
exacerbation of Parkinsonian features or other clinically significant symptoms.
5.3 Case study #3
Mr. C. was a non-Hispanic white male 65–70 years of age recently diagnosed 
with Major Depressive Disorder, with history of cervical vertebral fusions C5–C7. 
His presenting symptoms included cognitive interference (short-term memory 
loss and difficulty word-finding), panic attacks, appetite suppression, generalized 
anxiety, frequent migraine headaches, feeling off balance, dysphoria, insomnia 
(onset, median and terminal waking), restless sleep (which his spouse described 
as yelling and striking out in his sleep), and constipation (for about 4 years). 
OTC and dietary treatments had not been effective for reducing the symptom of 
constipation. To treat his anxiety and depression, the patient had recently been 
prescribed Paroxetine HCl (Paxil) 30 mg daily, and for his panic and anxiety, 
clonazepam (Klonopin) 0.5 mg PRN. The patient was administered the MMSE, the 
QDRS and the LBCRS. His scores indicated mild cognitive impairment (MCI) and 
suggested neurocognitive impairment consistent with that found in patients with 
Lewy body disorders. The patient soon began to complain of increasing difficulties 
with balance, gait, and weakness. His depression increased, and he began to report 
suicidal ideation. He stated that his appetite suppression and constipation had both 
increased. During the same time frame, the patient’s cognitive impairment escalated 
rapidly. The combination of symptoms including MCI, rapid cognitive changes, 
balance/gait impairment, late-life onset depression and anxiety, weakness, appetite 
suppression, constipation, and sleep disturbance (possible REM sleep behavior 
disorder or RSBD and/or REM sleep without atonia, or RSWA) is consistent with 
the diagnosis of NCDLB. A neurological evaluation and a sleep study were ordered. 
Although an MRI was unrevealing, the neurological assessment was confirmatory 
for MCI. The sleep study confirmed the diagnosis of RSBD/RSWA.
Paroxetine is known to have anticholinergic properties [134], so its use was 
discontinued. Sertraline 100 mg per day was prescribed, and within weeks was 
increased to 200 mg per day. The PRN dosage of Clonazepam was increased to 
0.75 mg. Abilify (aripiprazole) 1 mg per day was added to address the patient’s 
intractable depression. Topiramate 75 mg HS was prescribed for the migraine 
headaches. To address the sleep disturbance, melatonin 6 mg and Mirtazapine 
30 mg were prescribed for use at bedtime. It was hoped that mirtazapine might 
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potentiate the effects of the Sertraline, while reducing restlessness in bed. The 
patient reported reductions in depression. However, there appeared to be no 
reduction in RSBD/RSWA. To address the patient’s rapidly advancing cognitive 
impairment, Memantine was prescribed 10 mg morning and at night, which 
produced significant cognitive improvement. To address the balance issues, tremor, 
gait disturbance, and general weakness, carbidopa-levodopa (Sinemet) 25/100 mg 
was prescribed three times a day, soon producing improvement in motor function. 
However, during the same time period, the symptom of constipation intensified. 
The patient reported that the frequency of bowel movements had fallen to less than 
once per week. OTC and dietary remedies had not produced any improvement. 
During this time frame, the patient became impacted twice, and each time had to 
be treated in the emergency room using bowel voiding medications intended for 
colonoscopies or bowel surgical procedures.
Donepezil was prescribed at a starting dose of 2.5 mg per day. The patient 
reported that during the first 2 weeks, his bowel movement frequency had 
increased to once every other day. After 4 weeks, he reported that the frequency 
of his bowel movements had increased to once a day. There was no change in the 
frequency of bowel movements for the next 3 months, but the patient expressed 
concern that his appetite and bowel production were not adequate. In an effort to 
achieve further symptom improvement, the dosage of donepezil was increased to 
5 mg per day. Within days, there were improvements in appetite, volume of dietary 
intake, and bowel output. There was no increase in Parkinsonian features or other 
clinically significant symptoms.
Following the increase in donepezil to 5 mg daily, the patient and his spouse 
described significant improvement in his cognitive functioning, including word 
finding and short-term memory. The patient was again administered the MMSE, 
the QDRS and the LBCRS. His scores had improved significantly on all three instru-
ments, suggesting overall recovery of cognitive function.
5.4 Case study #4
Mr. D. was a non-Hispanic white male 75–80 years of age. He had recently been 
diagnosed with PD and Major Depressive Disorder, with history of hypercholes-
terolemia, arteriosclerosis, lower back surgery, coronary artery stent replacement, 
small bowel obstruction, peripheral vascular disease, and chronic lower back pain. 
His presenting symptoms included cognitive interference (short-term memory loss 
and difficulty with word-finding), generalized anxiety, blunted affect, appetite 
suppression, depression, passive suicidal ideation, lower back pain, weakness, 
hand tremor, motor retardation, difficulties with balance, tottering or shuffling 
gait, sleep disturbance (onset, median and terminal waking), and constipation. At 
intake, he reported the frequency of bowel movements at approximately twice a 
week. OTC and dietary treatments had not been effective in reducing his constipa-
tion. The patient stated that for several years, he had experienced difficulties with 
balance. He sought referral to an orthopedist, and ultimately underwent surgery. 
The patient reported that subsequent to the surgery, he experienced chronic lower 
back pain, which was significant enough to interfere with routine activities. He 
ceased routine physical exercise, reported increasing weakness over the past few 
months, lost confidence in his coordination, leading him to give up driving, and 
stated that his hand tremor had evolved to the extent that his handwriting was no 
longer legible. He described a deepening depression and the emergence of suicidal 
ideation. There was no report or evidence of symptoms consistent with RSBD or 
RSWA. However, the patient reported that the his constipation had increased and 
remained unresponsive to OTC or dietary remedies.
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The patient was administered the MMSE, the QDRS and the LBCRS. His scores 
suggested mild cognitive impairment (MCI) and neurocognitive impairment 
consistent with that found in patients with Lewy body disorders. The combination 
of symptoms including cognitive impairment, blunt affect, anxiety, late-life onset 
depression, motor retardation, hand tremor, handwriting changes, lower back 
pain, weakness, impaired/shuffling gait, difficulties with balance, sleep distur-
bance, appetite suppression, and constipation is consistent with the diagnosis of 
NCDLB. A neurological evaluation and a sleep study were ordered. The neurologi-
cal assessment confirmed the diagnosis of MCI, and an MRI indicated reduced 
cerebral (white matter) volume. The sleep study confirmed the diagnosis of RSBD/
RSWA.
Donepezil was prescribed at a starting dosage of 5 mg per day. After 2 weeks, the 
patient reported that the frequency of his bowel movements had increased to about 
every other day. Within 3 weeks, he reported that he was having bowel movements 
every day. He also reported that his appetite had significantly increased. There was 
no exacerbation of Parkinsonian features or other clinically significant symptoms.
6. Results
6.1 Case study initial results
In each of the four patients in the case studies, the use of donepezil significantly 
reduced the symptom of constipation within a few weeks, without increasing 
Parkinsonian features or other clinically significant symptoms. There was also 
significant reduction of constipation for each of the two patients prescribed carbi-
dopa-levodopa. In addition, when the patient whose NCDLB symptom progression 
was most advanced was readministered the MMSE, the QDRS and the LBCRS, 
he scored higher on all three tests, indicating improvements in overall cognitive 
functioning, word finding, and short-term memory.
6.2 Case study six-month follow-up
The symptom status of the four patients was reviewed 6 months later. The two 
patients in case studies #1 and #2 showed no symptom change. The two patients in 
case studies #3 and #4 each showed evidence of Lewy body symptom progression, 
including increased cognitive interference (short-term memory loss and difficulty 
with word-finding), generalized anxiety, dysphoric mood, blunted affect, appe-
tite suppression, passive suicidal ideation, sleep disturbance (onset, median and 
terminal waking, REM sleep behavior disorder or RSBD and/or REM sleep without 
atonia, or RSWA), and Parkinsonian features (motor retardation, joint and muscle 
pain, reduced range of motion, diminished strength and coordination, increased 
tremor, gait disturbances, and difficulties with balance). Constipation, however, 
had not increased for any of the patients, nor was there evidence of new symptom 
emergence. Coincident with the 6 month symptom review, the patient in case study 
#3 had his dosage of donepezil doubled, from 5 to 10 mg orally administered daily, 
with the intention of mitigating his neurocognitive symptom progression.
6.3 Case study twelve-month follow-up
Twelve months after the initial findings had been reported, the symptom status 
of the four patients was again reviewed. During the interval between the 6 month 
and 12 month reviews, there was no apparent progression of Lewy body symptoms 
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in any of the four patients. At 6 months, the patient in case study #3 had his dosage 
of donepezil doubled (from 5 to 10 mg orally administered daily) to address the 
progression of neurocognitive symptoms. At 12 months, he demonstrated reduced 
cognitive interference (short-term memory loss and difficulty with word-finding), 
which appeared to be associated with the increase in his dosage of donepezil. 
No other symptom changes were evident in that patient. In the remaining three 
patients, no symptom progression or change was apparent. None of the patients 
exhibited new symptoms, or any increase in the symptoms of constipation, obstipa-
tion, or impaction.
6.4 Case study eighteen-month follow-up
At 18 months, the symptom status of each of the four patients in the case studies 
was again reviewed. There was no apparent progression of Lewy body symptoms 
in any of the four patients between the 12 month and 18 month reviews. In the 
patient in case study #3, whose Lewy body symptoms had progressed at 6 months, 
doubling the dosage of donepezil (from 5 to 10 mg orally administered daily) 
continued to be associated with reduced cognitive interference (short-term memory 
loss and difficulty with word-finding). No other symptom changes were evident in 
that patient. In the remaining three patients, no symptom progression or change 
was apparent. None of the patients exhibited new symptoms, or any increase in the 
symptoms of constipation, obstipation, or impaction.
7. Summary, discussion, and conclusions
One of the consequences of greater worldwide longevity has been an upsurge in 
the number of older adults living with neurocognitive disease [1, 2]. Currently, over 
50 million people in the world have neurocognitive diseases, almost 20 million of 
which have Parkinson’s Disease (PD) or Neurocognitive Disorder with Lewy Bodies 
(NCDLB). The overall number of people in the world with neurocognitive disease 
is expected to exceed 131.5 million by year 2050, with about 43 million of those 
attributable to PC or NCDLB [1, 2, 4, 5].
In 2015, the global cost of providing treatment and long-term care to people with 
neurocognitive disease was about $818 billion. That figure is expected to exceed $4 
trillion by year 2050 [2–4]. The cost of providing treatment and long-term care to 
patients with PD and NCDLB exceeds one third of the total global expense, because 
Lewy body diseases like PD and NCDLB encompass a large and varied number of 
cognitive, motor, and autonomic symptoms [8]. Lewy bodies are abnormal intracel-
lular aggregations of α-synuclein protein [9] that can affect any neurotransmitter 
pathway in any one or all of the ANS, CNS, PNS, or ENS.
Gastric slowing due to α-synucleopathology is an almost universal feature of PD 
and NCDLB, but is often not a focus of treatment [18]. As the symptoms of consti-
pation, obstipation, and impaction progress, they negatively impact mobility, sleep, 
cognition, and mood, increasing the cost of care and debilitating or dramatically 
reducing the quality of life for patients [11–17]. From a phylogenetic perspective, 
the central nervous system and all its higher cortical functions exist solely in service 
of the alimentary canal. The impact that constipation, obstipation, and impaction 
have on the quality of life cannot be overstated.
When constipation, obstipation, and impaction are addressed for patients 
with α-synucleopathology, conventional over-the-counter treatments are usually 
recommended, even though research has shown that such treatments are ineffective 
for patients with PD and NCDLB [12]. Such treatment suggests unawareness that 
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constipation is considered a common feature of α-synucleopathology, likely prodro-
mal for Lewy body (α-synuclein) pathology, often manifesting years before other 
α-synucleopathology [17, 21, 37, 54–57]; and that in constellation with late-life onset 
depression, cognitive impairment, and RBD/RSWA, constipation may be a reliable 
biomarker for α-synucleopathology [18, 24, 25, 29, 30].
In this chapter, a description was given of α-synucleopathology in the 
Lewy body diseases PD and NCDLB, and its symptomatic manifestations 
in the ENS. Explanation was made for the specific mechanisms through 
which α-synucleopathology interferes with gastric motility, as well as 
the specific mechanisms through which specific medications can address 
α-synucleopathology in the ENS. It was hypothesized that α-synuclein patho-
logical impairment of the MP and CSMP in patients with NCDLB and PD might 
be mitigated with the use of the AchEI donepezil, which has demonstrated 
effectiveness for boosting cholinergic activity, and mitigating symptoms of 
α-synucleopathology in patients with PD and NCDLB. The expected outcomes 
included reduction of the symptoms of constipation, obstipation, and impac-
tion. It was also hypothesized that donepezil might have specific benefit for 
reducing constipation in PD and NCDLB patients for whom L-dopa agents like 
carbidopa-levodopa are prescribed.
A series of case studies was then presented, in which four patients at varying lev-
els of disease progression with PD and NCDLB were orally administered donepezil 
in daily doses varying from 5 to 10 mg. Results indicated that the use of donepezil 
was associated with significant reduction in the symptoms of constipation, obstipa-
tion and/or impaction. Although there had been progression of cognitive interfer-
ence, movement disorders, and other Lewy body pathology in two of the patients 
(case studies #3 and #4), symptom reduction for constipation, obstipation and/or 
impaction for all four patients was consistent over time, assessed at intervals of two, 
four and 6 weeks, and later, at intervals of 6, 12, and 18 months [135–137].
The findings support the hypothesis donepezil might reduce α-synuclein 
pathological impairment of the MP and CSMP in patients with NCDLB and 
PD, increasing bowel motility and reducing the symptom of constipation. The 
findings also support the hypothesis that donepezil might have specific benefit 
in reducing constipation in PD and NCDLB patients for whom L-dopa agents 
like carbidopa-levodopa are prescribed. It appears that donepezil achieves such 
symptom reduction through its “dual action:” in part, specifically and reversibly 
limiting the action of the acetylcholine-hydrolyzing enzyme acetylcholinesterase 
[129, 130]; and in part, by independently facilitating neuronal nicotinic ace-
tylcholine receptors [131]. The combined effect of these two mechanisms is to 
effectively increase acetylcholine levels and mitigate the symptoms of cholinergic 
impairment [128].
The reduction of constipation, obstipation, and impaction without exacerba-
tion or emergence of other symptoms in all four patients over an 18 month period 
suggests that donepezil might be efficacious for treating these symptoms over 
an extended time frame, including its use for patients simultaneously taking 
carbidopa-levodopa. The findings are also consistent with previous research dem-
onstrating that donepezil is effective for slowing or reversing cognitive symptom 
progression in Lewy body disorders, including short-term memory loss, difficulty 
with word-finding, hallucinations, and cognitive interference [107, 110–123]. To 
increase our understanding of α-synucleopathology and its role in PD and NCDLB, 
the symptoms of constipation, obstipation, and impaction, and effective medical 
interventions, further research is suggested, including longitudinal case studies, as 
well as large data set analyses using larger numbers of subjects matched for diagno-
sis, age, gender, and other variables.
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